Michał Sołowow invested in OncoArendi Therapeutics Sp. z o.o.

 On January 15, 2015 Michał Sołowow invested in OncoArendi Therapeutics Sp. z o.o. via  the IPOPEMA 112 FIZAN fund.

OncoArendi is a dynamically growing biotechnological company, which develops innovative anti-inflammatory and antitumor drugs with unique mechanisms of actions. Twelve million PLN obtained from Series A investors, with Michał Sołowow as leading investor, will allow the company to work on its key programmes for the next three years: potential asthma therapy and a group of new compounds stimulating the anti-tumour response of the human immune system. About 4 million Poles and 300 million people worldwide suffer from asthma with more and more children developing the disease. Currently used steroid therapies have severe side effects. At the same time every year cancer is diagnosed in more than 14 million patients and it remains the most frequent cause of death worldwide. In Poland both cancer incidents and death rate are the highest among European Union countries.
Apart from the company’s unique research programs and world leading position in the area of inhibitors of proteins called chitinases, investors were attracted to OncoArendi by its team of top medicinal chemists with many years of experience in pharmaceutical and biotechnology companies in the US, outstanding molecular biologists and successful managers with experience leading high-technology companies to IPO. Crucial for the investors was also The financial support, which the Company received from NCBR, was also important for investors, because it significantly lowers the risk of long term investment in scientific research.
OncoArendi is the first biotech investment for Michał Sołowow. This  sector still developing in Poland. Financing research aimed at developing innovative drugs is very risky, but if successful, the potential return on investment may be great. Acquisitions of New drug candidates, which have already entered clinical trials, may be acquired by global pharmaceutical companies for hundreds of  millions of dollars.
Investors and OncoArendi have joined forces to deliver to patients more effective and safer drugs than presently available therapies, along with company growth and substantial economic return.

meatnetadmMichał Sołowow invested in OncoArendi Therapeutics Sp. z o.o.
Czytaj więcej

Oncoarendi Therapeutics won over 25.5 million zloty

Oncoarendi Therapeutics as the leader of an academic – industrial consortium won over 25.5 million zloty in the second call for proposals of the National Center of Research and Development in the StrategMed program.
The aim of this project is to develop a conceptually novel therapeutic approach in cancer treatment – small molecule immune-modulators to knock-down the ability of tumors to escape immune surveillance.
The project was ranked second among twelve proposals recommended for funding and a total of one hundred and nine evaluated project proposals.

The consortium partners include Medical University of Warsaw, Nencki Institute of Experimental Biology, Institute of Biochemistry and Biophysics, International Institute of Molecular and Cell Biology, commercial partners – Nanovelos Ltd, Scanmed Hospital of St. Rafael, as well as subcontractors – Military Institute of Medicine, Oxford University, Weatherall Institute of Molecular Medicine.

   

meatnetadmOncoarendi Therapeutics won over 25.5 million zloty
Czytaj więcej

OncoArendi receives a grant of over 7 mln PLN for its lead drug discovery program

 OncoArendi will benefit from over 7 M in public financing within the Innovative Economy Operational Program, Action 1.4: “Support for targeted research projects”. The project, entitled “Selective inhibitors of acidic mammalian chitinase (AMCase) as potential therapy for asthma” will be executed in collaboration with several scientific and commercial contractors, including, among others, Medical University of Warsaw, Brown University, USA, Institute of Biophysics and Biochemistry and the Nencki Institute of Experimental Biology, Polish Academy of Science, the International Institute of Molecular and Cell Biology as well as a synthetic chemistry CRO – TriMen Chemicals SA. The project will result in identification of a clinical candidate to be registered as an investigational new drug for clinical trials.

 

meatnetadmOncoArendi receives a grant of over 7 mln PLN for its lead drug discovery program
Czytaj więcej

OncoArendi Therapeutics has signed an exclusive agreement

with one of the top 10 U.S. Universities for the development of inhibitors of new, validated biological targets for the treatment of anti-inflammatory diseases. Further details of this agreement cannot be disclosed at this time.

meatnetadmOncoArendi Therapeutics has signed an exclusive agreement
Czytaj więcej

OncoArendi Therapeutics has closed its angel investment round raising

through emission and acquisition of new shares, a total of 3.5 million PLN (approx. 1.1 million USD). Proceeds from this round will be used to supplement public financing in two ongoing discovery programs and launch a third program for the development of anti-inflammatory drug candidates.

meatnetadmOncoArendi Therapeutics has closed its angel investment round raising
Czytaj więcej

The Nencki Institute of Experimental Biology has just signed

a contract with the National Center for Research and Developemnt for co-financing of a 7 Miliion PLN, 30-month collaborative preclinical research and development project of a propriatary oncology drug candidate – OAT449. OncoArendi Therapeutics will be the sole owner of the research results of this joint project and plans to bring the preclinical work through GLP toxicology to the pre-ind stage. The funding source is Action 1.3.1 of the Innovative Economy Operational Programme.

meatnetadmThe Nencki Institute of Experimental Biology has just signed
Czytaj więcej

A patent application for the OAT-449

drug candidate is simultaneously filed by OncoArendi Therapeutics with the United States Patent and Trademark Office (USPTO) and with the Patent Office of the Republic of Poland.

meatnetadmA patent application for the OAT-449
Czytaj więcej